Emergent BioSolutions Inc. (EBS) Stock Forecast & Analysis

Real-time stock price, financial statements, consensus target price, insider trading, and technical analysis for Emergent BioSolutions Inc. (EBS:NYSE), powered by AI.

Current Price
$8.32
P/E Ratio
8.5
Market Cap
445M
Sector
Healthcare
What is the Emergent BioSolutions Inc. stock price forecast?

Emergent BioSolutions Inc. is currently trading at $8.32. View real-time AI analysis on Alpha Lenz.

What is Emergent BioSolutions Inc. insider trading activity?

View the latest insider trading data for Emergent BioSolutions Inc. on Alpha Lenz.

What is Emergent BioSolutions Inc.'s P/E ratio?

Emergent BioSolutions Inc.'s P/E ratio is 8.5.

Emergent BioSolutions Inc.

NYSE · EBS
$8.32-0.07(-0.83%)Pre-marketNYSE regular session 09:30–16:00 ET
Ask about Emergent BioSolutions Inc.'s future dividend policy...
Alpha Chat Insight

Emergent BioSolutions Inc. trades at a P/E of 8.5 (undervalued) with solid ROE of 10.5%.

Ask for details

Company Overview

Emergent BioSolutions Inc. is a global life sciences company that primarily focuses on the development, manufacturing, and distribution of a wide array of medical products. These products are designed to address public health threats including chemical and biological agents, and infectious diseases. As an important player in the health sector, the company is known for its specialized work in vaccines, antibody therapeutics, and medical devices. Notably, Emergent BioSolutions is a key supplier of biodefense solutions, including anthrax and smallpox vaccines, which are critical to national security programs. The company’s operations span pharmaceutical manufacturing, research, and development, and it works in partnership with both government and commercial entities. Headquartered in Gaithersburg, Maryland, Emergent BioSolutions plays a pivotal role in emergency preparedness, health security, and response solutions, underscoring its importance in global health initiatives and the broader pharmaceutical industry.

CEOMr. Joseph C. Papa Jr., M.B.A., R.Ph.
SectorHealthcare
IndustryDrug Manufacturers - Specialty & Generic
Employees900

Company Statistics

FY 2025

Profile

$445.12MMarket Cap
$705.20MRevenue
0.00Shares Out
900Employees

Margins

53.74%Gross
37.20%EBITDA
15.92%Operating
11.74%Pre-Tax
7.46%Net

Valuation

8.46P/E
0.85P/B
0.63EV/Sales
3.10EV/EBITDA
2.84P/FCF

Growth (CAGR)

-13.14%Rev 3Yr
-13.57%Rev 5Yr
N/AOp Inc 3Yr
-23.85%Op Inc 5Yr
N/ANet Inc 3Yr
-29.68%Net Inc 5Yr

Returns

3.88%ROA
10.46%ROE
10.49%ROIC

Financial Health

$205.40MCash & Cash Equivalents
$590.60MNet Debt
152.32%Debt/Equity
N/AInterest Cov

Frequently Asked Questions

Emergent BioSolutions Inc. (ticker: EBS) is a company listed on NYSE in the Healthcare sector (Drug Manufacturers - Specialty & Generic). It has approximately 900 employees. Market cap is $445M.

The current price is $8.32 with a P/E ratio of 8.46x and P/B of 0.85x.

ROE is 10.46% and operating margin is 15.92%. Annual revenue is $705M.

Alpha Lenz
Singapore
Treasurer Pte Ltd | License: 202346277E
9 Straits View Marina One West Tower #05-07 Singapore 018937
contact@treasurer.co.kr
©2026 Treasurer Pte Ltd. All rights reserved.
Emergent BioSolutions Inc. (EBS) Stock Forecast 2026 $8.32 — Price, Financials & Analyst Targets | Alpha Lenz